Navigation Links
Transplanted fatty livers associated with worse prognosis for patients with HCV
Date:1/13/2009

A new study suggests that patients with hepatitis C (HCV) who need a liver transplant should not receive an organ with high levels of fatty deposits (a.k.a. hepatic steatosis). HCV recurrence was more frequent and earlier among those transplanted with such livers. These findings are in the January issue of Liver Transplantation, a journal published by John Wiley & Sons. The article is also available online at Wiley Interscience (www.interscience.wiley.com).

Recently, reports have revealed that survival rates among HCV-infected liver transplant recipients are decreasing. This is particularly troubling because HCV is the most common indication for liver transplantation in Western countries. In these places, the donor population is more likely to be overweight, and therefore more likely to have fatty livers. These organs are highly susceptible to cold or warm ischemia injury, leading researchers to hypothesize that liver steatosis may be affecting the outcomes for transplant recipients.

Researchers, led by Javier Briceo and Ruben Ciria of Cordoba, Spain, sought to determine the influence of donor liver steatosis on outcomes for HCV patients who received them. They included 120 patients who underwent liver transplantation as a result of HCV-cirrhosis between 1995 and 2005. Donor steatosis was categorized as absent (0-10 percent), mild (10-30 percent), moderate (30-60 percent) or severe (greater than 60 percent).

"Our results show a direct relationship between marginal donor, graft steatosis and a more frequent, severe and earlier viral recurrence after orthotopic liver transplantation for HCV-related cirrhosis," the authors report. Patient survival was significantly worse when graft steatosis was 30 percent or more.

Survival of the graft was inversely proportional to donor liver steatosis. After three years, graft survival was 72 percent for transplant recipients whose donor livers had no steatosis, 58 percent for mild, 43 percent for moderate and 42 percent for severe. The most profound decline in graft survival occurred when donor livers contained greater than 30 percent steatosis and were subjected to more than 12 hours of cold ischemic time.

The authors compared their results to outcomes of liver transplantations in individuals with alcohol-induced cirrhosis, as opposed to HCV. They found that donor steatosis greater than 30 percent did not reduce graft survival in these non-HCV patients.

"Further multicenter studies and a global consensus may be necessary to finally assess if the use of expanded criteria grafts is safe into HCV-positive recipients, as well as if nowadays the organ allocation system should need a change for this cohort of patients," they conclude.

An accompanying editorial by Mitchell Shiffman and Nevin Yilmaz of Virginia Commonwealth University Medical Center raises concerns about the study's conclusions. It points out that all patients did not undergo liver biopsies at specified time intervals, and there was not enough data on the patients with alcohol-induced cirrhosis to be sure that the populations were comparable.

Still, they were intrigued by the observation that the combination of donor graft steatosis and a prolongation in cold ischemic was associated with severe reperfusion injury.

"We strongly suggest that cold ischemia time should be limited when the donor graft contains greater than 30 percent steatosis and such grafts should only be utilized with caution for patients with chronic HCV," they conclude.


'/>"/>

Contact: Sean Wagner
medicalnews@bos.blackwellpublishing.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Circulating fats kill transplanted pancreas cells, study shows
2. Transplanted Bone Marrow Cells Aid Nerve Regeneration
3. Transplanted Liver Lining Cells May Cure Hemophilia
4. New approaches to protecting transplanted organs make first steps toward patients
5. Diet Change Can Curb Fatty Liver Disease
6. Attenuation of NASH by stimulation of free fatty acid metabolism
7. Drops of Fatty Acid Curb Symptoms of Dry Eye Syndrome
8. Mayo Clinic proceedings highlights research about cardiovascular benefits of omega-3 fatty acids
9. Omega-3 Fatty Acids Protect the Spinal Cord, Heart, Brain and Eyes
10. Dogs and Cats Need Omega-3 Fatty Acids Just as Humans Do - Nordic Naturals Offers Premium Fish Oil to Supplement Pets Diet!
11. Omega-3 Fatty Acids Wont Prevent Crohns Relapse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... The American ... Network (AHN), a Highmark Health company, to its Board of Trustees for a ... not-for-profit association of health care provider organizations and individuals that are committed to the ...
(Date:8/20/2017)... ... 20, 2017 , ... A total solar eclipse will occur across the U.S. on ... moon moves between the sun and Earth. This rare event will be magnificent to witness, ... keep you safe on the road during the total eclipse of the sun. , 1. ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... Jr., will feature the Aurum Group in an upcoming episode, slated to air ... of Innovations will feature the Aurum Group; a company committed to supporting dentistry ...
(Date:8/19/2017)... New York, New York (PRWEB) , ... August ... ... Fruit Street Health has announced that it is the first organization with pending ... the CDC’s National Diabetes Prevention Program (“DPP”) via group telehealth classes and live ...
(Date:8/19/2017)... NJ (PRWEB) , ... August 19, 2017 , ... ... Park, NJ, is a diverse community of over 1,000 passionate employees, caregivers, volunteers, ... aging. After Parker at Stonegate changed ownership, it was time to refresh the ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... , Aug. 17, 2017 Bio-Ess Laboratories, LLC Chief Science Officer, ... titer and present new data on Cell-Ess® Universal Titer Boost ... Boston, MA August 21-25.  The Bioprocessing Summit convenes more ... challenges. ... ...
(Date:8/15/2017)...  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... stages of an IPO. The United States ... cost of a prescription epilepsy drug being $450.00-$1200.00 for a one month ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion on ...
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
Breaking Medicine Technology: